Menu
No results found.
“Patience reduces risk more reliably than prediction.”
Weekly Share Price & Valuation Overview
Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services. In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer. Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- CHF 119.97M
- Enterprise Value Operating value: market cap + total debt − cash.
- CHF 269.91M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- CHF 834.88K
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- CHF 549.52K
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- CHF 0.15
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 4.69
- Shares Outstanding
- 5.77M
- Float Shares
- 2.89M
- Implied Shares Outstanding
- 5.77M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-20.67%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
65.82%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
41.06%
- ROA Return on assets: net income ÷ total assets.
-
-2.30%
- ROE Return on equity: net income ÷ shareholder equity.
-
7.54%
- Revenue Growth Year-over-year revenue growth.
-
-24.30%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
94.70%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
62.80%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.52
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.15
- Total Cash Cash and equivalents.
- CHF 99.03K
- Total Debt Short + long-term interest-bearing debt.
- CHF 59.32M
- Net Debt Total debt − cash (negative = net cash).
- CHF 59.22M
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- CHF -421.51K
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-50.49%
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.